Prosecution Insights
Prosecution Insights
Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Kyorin Pharmaceutical Co., Ltd. has 1 pending office action in the Chemistry & Materials technology area. This prosecution involves a distinct examiner and a distinct art unit. The current data shows a focused and low-volume prosecution pipeline for the company. This allows for a concentrated effort on the specific technical issues associated with the pending application.
The busiest examiner for the portfolio is ESPERON, NATHAN GREGORY, who is responsible for 1 pending office action. This action represents the total pending workload for the company. The company's immediate patenting goals in this area are tied to the review process of this specific examiner. By tailoring their responses to the distinct examiner and the distinct art unit involved, the company can maximize its chances of a favorable outcome. This streamlined prosecution profile minimizes the administrative burden and allows for a direct engagement with the patent office's technical staff.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ESPERON, NATHAN GREGORY | 1 | 41.0% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18020377 | NUCLEIC ACID AMPLIFICATION CHIP | ESPERON, NATHAN GREGORY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18020377 | NUCLEIC ACID AMPLIFICATION CHIP | ESPERON, NATHAN GREGORY | — |
| Art Unit | Apps |
|---|---|
| 1700 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18020377 | NUCLEIC ACID AMPLIFICATION CHIP | ESPERON, NATHAN GREGORY | 1700 | §103§112 | Final Rejection | — | Pending | Feb 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial